XBIO — Xenetic Biosciences Income Statement
0.000.00%
- $6.27m
- -$1.55m
- $2.54m
- 42
- 42
- 41
- 37
Annual income statement for Xenetic Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.017 | 0.437 | 1.16 | 1.71 | 2.54 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 12.9 | 14.4 | 6.91 | 8.42 | 7.06 |
Operating Profit | -12.9 | -13.9 | -5.75 | -6.72 | -4.52 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.8 | -13.8 | -5.65 | -6.55 | -4.13 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.8 | -10.9 | -5.65 | -6.55 | -4.13 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.8 | -10.9 | -5.65 | -6.55 | -4.13 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.1 | -10.9 | -5.65 | -6.55 | -4.13 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -37.3 | -7.64 | -5.49 | -4.61 | -2.71 |